Aurinia Early Urinary Protein Reduction Predicts Response
Status:
Completed
Trial end date:
2017-02-17
Target enrollment:
Participant gender:
Summary
An exploratory study assessing the ability of biomarkers measured at 8 weeks to predict
clinical response over 24 and 48 weeks in subjects taking voclosporin 23.7 mg twice daily
(BID) in combination with standard of care in patients with active lupus nephritis